The leading drug in Gentas Small Molecule program is Ganit.

For treatment of symptomatic patients with cancer hypercalcemia that is resistant to moisture G4544, G4544, an oral formulation of the active ingredient in Ganite, studies have studies have recently listed as potential treatment for diseases accelerated bone loss accelerated bone loss. The company is also developing tesetaxel, a novel, orally absorbed, semi – synthetic taxane that. Within the same class of drugs as paclitaxel and docetaxel and and Genasense are on a named-patient basis in countries outside the United States.

.. Genta receives Complete Response Letter From FDA to Amended Application of Genasense in patients with chronic lymphocytic leukemiaGenta Incorporated today announced that the company achieved complete response letter from the Office of Oncology Food and Drug Administration Food and Drug Administration regarding the company New Drug Application is of by Genasens plus chemotherapy in patients with chronic lymphocytic leukemia . Indicated in their letter OODP that the department does not approve the NDA in its present form and suggested the need for further clinical study. – We are disappointed with the official decision, said Dr. Raymond P. Warrell, Genta ‘s Chief Executive Officer. We believe that Genasense amply demonstrated its efficacy and safety in patients with relapsed or refractory CLL in a carefully designed and well-conducted randomized clinical trial While our primary focus for Genasense remains the timely completion our randomized trial in melanoma.Of his speech Promotes Medicare Prescription Drug Benefit in Weekly Radio AddressBush am Samstag his weekly radio address urged Medicare beneficiaries of the new Medicare to enroll take advantage prescription medicine used, calling it ‘the biggest advance ‘in health care for older people, Medicare as of creation in 1965, report Reuters news agency (Reuters, admission into the program will begin on Tuesday and lasts until 15 May 2006.